What cognitive and functional impairments occur in dementia, and what is the first-line pharmacologic therapy for Alzheimer's disease in an elderly patient without contraindications?

Impairments in Dementia and First-Line Pharmacologic Therapy

For an elderly patient with Alzheimer's disease without contraindications, initiate treatment with a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) at the highest tolerable dose, as this represents the evidence-based first-line pharmacologic therapy. 1

Cognitive and Functional Impairments in Dementia

Dementia manifests as an acquired loss of cognition across multiple domains that is severe enough to impair social or occupational function. The core impairments include:

Cognitive Deficits

• Memory impairment - particularly episodic memory in early Alzheimer's disease
• Language dysfunction - word-finding difficulties, comprehension problems
• Executive function deficits - impaired planning, organization, and problem-solving
• Attention and working memory problems
• Visuospatial impairments - spatial disorientation, recognition disorders 2

Functional Impairments

• Activities of daily living (ADL) decline - progressive inability to manage self-care and instrumental activities
• Social and occupational dysfunction - inability to maintain previous levels of functioning 2

Behavioral and Psychological Symptoms

• Apathy, anxiety, depression
• Social withdrawal
• Emotional fluctuations with agitation
• These behavioral and psychological symptoms of dementia (BPSD) may be early warning signs 3

First-Line Pharmacologic Treatment Algorithm

For Mild to Moderate Alzheimer's Disease

Start with a cholinesterase inhibitor as standard first-line therapy 1, 4. The three FDA-approved options are:

• Donepezil (5-10 mg/day)
• Rivastigmine (transdermal or oral formulation)
• Galantamine

Key principle: Use the highest tolerable dose 5. There is no convincing evidence of superiority of one cholinesterase inhibitor over another, so selection should be based on:

• Side effect profile
• Drug interaction potential
• Patient tolerance
• Formulation preference 5

Expected Treatment Effects

The evidence demonstrates statistically significant but modest benefits 1:

• Cognitive improvement: Mean difference of -2.67 points on ADAS-Cog scale (though below the 4-point threshold for clinically important improvement) 1
• Global function: Improvement on clinician-rated impression of change (CIBIC-plus) 1
• Activities of daily living: Statistically significant improvements demonstrated 1
• Behavioral symptoms: No significant effect on neuropsychiatric symptoms 1

For Moderate to Severe Alzheimer's Disease

Add memantine (NMDA receptor antagonist) either as:

• Monotherapy for moderate Alzheimer's disease
• Combination therapy with a cholinesterase inhibitor for moderate disease
• Monotherapy for severe Alzheimer's disease 4

Dosing Strategy

Titrate gradually to minimize gastrointestinal side effects (nausea, vomiting, diarrhea, anorexia). These can be managed by:

• Slow dose escalation
• Administration with food
• Adequate hydration
• Judicious antiemetic use if needed 6

For donepezil specifically, the 10 mg/day dose shows marginally larger benefits than 5 mg/day, while the 23 mg/day dose offers no additional benefit over 10 mg/day but increases adverse events 7.

Important Clinical Considerations

Contraindications and Cautions

True contraindication: Known hypersensitivity to the specific drug or its derivatives 6

Use with caution in:

• Severe liver disease (note: tacrine is hepatotoxic and not recommended)
• Preexisting bradycardia
• Peptic ulcer disease
• Asthma or chronic obstructive pulmonary disease 6

Monitoring and Duration

• Monitor cognitive and functional status every 6 months 4
• Continue treatment until there are no meaningful social interactions and quality of life has irreversibly deteriorated 4
• Treatment effects are typically assessed at 24-26 weeks 1

Common Pitfall

Withdrawals are more common with treatment (24% vs 20% placebo), and adverse events occur more frequently (72% vs 65% placebo) 7. However, these modest side effects should be weighed against the demonstrated cognitive and functional benefits.

Adjunctive Therapy

High-dose vitamin E (1000 IU twice daily) may be added based on evidence showing it slows AD progression, given its low cost and safety profile 6.